Skip to main content

Drug Interactions between Baycadron and netupitant / palonosetron

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

dexAMETHasone netupitant

Applies to: Baycadron (dexamethasone) and netupitant / palonosetron

ADJUST DOSE: Coadministration with netupitant or its prodrug, fosnetupitant, may significantly increase the plasma concentrations of dexamethasone. The proposed mechanism is netupitant inhibition of dexamethasone metabolism via CYP450 3A4. When a single 300 mg dose of netupitant was coadministered with a dexamethasone regimen consisting of 20 mg on day 1, followed by 8 mg twice daily from days 2 to Day 4, mean dexamethasone systemic exposure (AUC) was increased by 1.7-fold on day 1 and up to 2.4-fold on day 2 and day 4. The duration of the effect was not studied beyond 4 days.

MANAGEMENT: Dexamethasone should be administered at a reduced dosage when used with netupitant or fosnetupitant. For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, dexamethasone should be dosed according to the product labeling for netupitant-palonosetron or fosnetupitant-palonosetron.

References

  1. (2014) "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc
  2. (2018) "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer